Takeaways: Apotex’s Denoza biosimilar gives Canada a home‑grown denosumab option, intensifying price and tender pressure on Amgen’s Prolia in a market with 2.3M osteoporosis ...
Takeaways: Health Canada’s CTA clearance positions Affinia among the first wave of next‑gen cardiac gene therapy players, using a bespoke AAV capsid to go after genetically defined BAG...
Takeaways: This tie-up effectively turns WELL’s cardiologist network into an on‑demand, paid “virtual read” service layered on top of AliveCor’s at‑home ECG hardware and AI, direc...
Takeaways: CLOBIVIS modestly strengthens Apotex’s position in Canada’s post‑cataract segment and helps it move up the value chain in eye care beyond pure generics. In marke...
